Rosacea is a chronic neurovascular and inflammatory disorder of the central face. The hallmark is persistent redness across the cheeks, nose, chin, and central forehead, often with visible telangiectasias (small dilated blood vessels) and intermittent flares of papules and pustules that can be mistaken for acne. Unlike acne, rosacea spares the chest and back and does not produce blackheads, and it carries a strong neurovascular component — flushing, burning, and stinging triggered by heat, sunlight, alcohol, and stress — that responds to a fundamentally different treatment strategy.
For patients in St. Petersburg and the broader Tampa Bay area, rosacea tends to be unusually persistent because two of the strongest known triggers — ultraviolet exposure and ambient heat — are with us most of the year. Patients moving here from northern climates often experience a noticeable worsening within their first Florida summer.
What we now believe is going on biologically
The older view of rosacea as simply "easily flushed skin" has been replaced by a more complete picture. Three overlapping processes drive the disease:
- Dysregulated innate immunity: Patients with rosacea express elevated levels of cathelicidin antimicrobial peptides and the protease kallikrein-5 in facial skin. Cleavage of cathelicidin produces a fragment (LL-37) that is directly pro-inflammatory and pro-angiogenic, explaining both the redness and the formation of new abnormal vessels.
- Neurovascular instability: Sensory nerves in rosacea skin are hyper-reactive. Heat, capsaicin from spicy foods, alcohol, exercise, and emotional stress activate TRPV1 and TRPA1 receptors on these nerves, triggering vasodilation and the characteristic flushing response.
- Density of Demodex folliculorum mites: These microscopic mites live in the pilosebaceous units of nearly all adults, but rosacea patients harbor markedly higher densities. The mites and their bacterial cargo appear to perpetuate the inflammatory cycle.
Genetics are clearly involved. The strongest associations are with fair skin and northern European ancestry, but rosacea occurs across all skin types and is frequently underdiagnosed in patients with darker skin because the erythema is harder to see.
The four clinical subtypes
Most patients have features of more than one subtype, but it is useful to think about them separately because treatment differs.
Erythematotelangiectatic rosacea (ETR)
Persistent central facial redness, easy flushing, visible vessels, and skin that stings or burns with topical products. This is the most common presentation and the most difficult to treat with medication alone.
Papulopustular rosacea
Erythema plus inflamed papules and pustules concentrated on the central face. Comedones (blackheads) are absent — that is the single most useful clinical distinction from acne. This subtype responds best to anti-inflammatory therapy.
Phymatous rosacea
Sebaceous hyperplasia and fibrous tissue thickening, most often of the nose (rhinophyma). Predominantly affects men. Early intervention is much more effective than waiting until tissue thickening is established.
Ocular rosacea
Burning, gritty, light-sensitive eyes; recurrent styes and chalazia; meibomian gland dysfunction; and chronic blepharitis. Roughly half of rosacea patients have ocular involvement, and it is often missed because the eye symptoms predate the skin findings.
Triggers worth identifying
Trigger identification is genuinely useful because avoidance can reduce flare frequency more than any single medication. Common triggers, in rough order of frequency:
- Sun exposure (essentially universal in Florida patients)
- Heat — ambient, hot showers, saunas, hot drinks
- Alcohol, especially red wine
- Spicy food and capsaicin
- Emotional stress
- Exercise — particularly intense outdoor exercise in the heat
- Cosmetic products containing alcohol, witch hazel, menthol, eucalyptus, peppermint, or fragrance
- Topical corticosteroids on the face, which paradoxically worsen rosacea over time
A two-week trigger diary is a low-cost diagnostic tool and is often more revealing than the patient expects.
Conditions rosacea can be confused with
- Acne vulgaris — presence of comedones, involvement of chest/back, younger age of onset
- Seborrheic dermatitis — greasy yellow scale concentrated in the nasolabial folds and eyebrows
- Perioral dermatitis — papules clustered around the mouth, often triggered by topical steroid use
- Lupus erythematosus — malar rash that respects the nasolabial folds, photosensitivity, systemic symptoms; antinuclear antibody testing is appropriate when in doubt
- Carcinoid syndrome — rare; flushing with diarrhea and wheezing
If facial redness is associated with joint pain, fatigue, hair loss, mouth ulcers, or photosensitive rashes elsewhere on the body, we test for lupus before treating empirically for rosacea.
Treatment
Skin care foundation
Treatment that ignores the skin care basics rarely works. The foundation is:
- Gentle, fragrance-free cleanser used twice daily with lukewarm water
- A bland fragrance-free moisturizer applied while the skin is still damp
- Broad-spectrum mineral sunscreen (zinc oxide or titanium dioxide) with SPF 30 or higher every morning, reapplied if outdoors — chemical sunscreens often sting rosacea-affected skin
- Discontinuation of toners, exfoliants, retinoids during flares, and anything that stings on application
Topical prescription therapy
- Metronidazole 0.75% or 1% gel or cream — the long-established first-line anti-inflammatory topical, used once or twice daily
- Ivermectin 1% cream (Soolantra) — once-daily; targets Demodex mites and inflammation, particularly effective for papulopustular rosacea
- Azelaic acid 15% gel or foam (Finacea) — anti-inflammatory and lightly comedolytic; useful when there is overlap with acne
- Brimonidine 0.33% gel (Mirvaso) — constricts blood vessels and reduces redness for about twelve hours; helpful as needed for events but can cause rebound erythema in some patients
- Oxymetazoline 1% cream (Rhofade) — similar use case to brimonidine, often with less rebound
Oral therapy
- Low-dose doxycycline 40 mg modified-release (Oracea) — sub-antimicrobial dose, used for its anti-inflammatory effect rather than as an antibiotic; preferred over higher antibiotic doses for chronic management
- Standard-dose doxycycline 100 mg daily — useful for moderate to severe papulopustular flares
- Isotretinoin (Accutane) — reserved for refractory phymatous and severe papulopustular disease, in consultation with dermatology
Procedural therapy
Persistent telangiectasias and background erythema do not improve with creams or pills; they require energy-based devices. Pulsed dye laser (PDL) and intense pulsed light (IPL) are well-established treatments and typically take a series of three to five sessions for satisfying results. Rhinophyma can be improved or corrected with CO2 laser ablation or electrosurgical contouring once the inflammatory component is quiet.
Ocular rosacea
Warm compresses to the eyelids twice daily, eyelid hygiene with diluted baby shampoo or a commercial lid cleanser, and artificial tears form the baseline. Low-dose doxycycline is the workhorse oral therapy. Cyclosporine 0.05% drops (Restasis) and lifitegrast (Xiidra) help in patients with associated dry eye. Persistent or vision-affecting cases warrant ophthalmology referral.
What patients can realistically expect
Rosacea is a chronic condition. Treatment controls it — it does not cure it — and most patients do best with a combination of trigger management, daily skin care, a topical anti-inflammatory, and (when needed) a short or low-dose oral course or laser treatment. With a stable regimen, the majority of patients reach a level where rosacea is no longer the first thing they think about in the morning or notice in the mirror.
When to see us
If over-the-counter approaches haven't worked, if you have eye symptoms along with the skin findings, if you've been using topical steroids on your face for any length of time, or if you'd like help building a sustainable regimen tailored to Florida's climate, schedule a visit. Contact us or book online.